Methemoglobinemia secondary prevention

	Methemoglobinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Methemoglobinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Methemoglobinemia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Methemoglobinemia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Methemoglobinemia secondary prevention
on Methemoglobinemia secondary prevention
Methemoglobinemia secondary prevention in the news
Blogs on Methemoglobinemia secondary prevention
Directions to Hospitals Treating Methemoglobinemia
Risk calculators and risk factors for Methemoglobinemia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aksiniya Stevasarova, M.D.

Overview

Secondary prevention consists of avoiding oxidizing agents in people with diagnosed G6PD deficiency or known congenital deficiency of the reductase enzyme.